RxDoctor Payments Data

Gregory Elsner, MD

Interventional Cardiology · Indianapolis, INNPI 1619941895

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,332 of the $4,922 with a category attached, or 67.7%. 11 manufacturers reported payments, led by Edwards Lifesciences at 35.9% of the total. Reporting peaked in 2019 at $2,021 and has fallen 57.7% since, to $855 in 2025. That places this record below the midpoint for interventional cardiology clinicians in IN, where the typical reported total is $6,172.

$4,922in general payments, 2019–2025

Across 37 payments — averaging $133.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$2K
  • Boston Scientific$1K
  • Abbott$888
  • Medtronic$230
  • Teleflex LLC$165
  • E.r. Squibb & Sons, L.L.C.$151
  • plus $452 from 5 others
$20,900in research payments, 2019–2025

Across 34 payments — averaging $614.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Daiichi Sankyo Inc.$21K

What the payments were for

  • Travel & lodging$1,56832%
  • Food & beverage$3,33268%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,922 in reported general payments places this provider in the 40th percentile of 170 interventional cardiology providers in Indiana.

See all interventional cardiology providers in Indiana

Medicare billing

Part B allowed, 2024
$164,238
Medicare patients
531
Services billed
1,400

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban165$199,264
XareltoRivaroxaban51$80,788
EntrestoSacubitril/Valsartan49$68,464
Repatha SureclickEvolocumab36$51,733
JardianceEmpagliflozin37$46,397
MultaqDronedarone Hcl31$34,533
BrilintaTicagrelor17$17,082
Ezetimibe211$5,278
VascepaIcosapent Ethyl13$4,532
ClopidogrelClopidogrel Bisulfate308$4,494
Atorvastatin Calcium355$3,912
Metoprolol Succinate287$3,659
Ranolazine ErRanolazine19$2,789
Eplerenone24$2,676
Carvedilol184$2,030

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →